Page 5 - லெய்செஸ்டர் ஜநரல் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Mar 16, 2021 Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to Begin Enrollment in the First Half of 2021 VANCOUVER, British Columbia and SEATTLE, March 16, 2021 (GLOBE NEWSWIRE) Chinook Therapeutics, Inc.. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the ALIGN Study, a pivotal phase 3 clinical trial evaluating the efficacy and safety of atrasentan, a potent and selective inhibitor of the endothelin A receptor. “The initiation of the phase 3 ALIGN Study is an important milestone for Chinook as we advance our pipeline of programs for rare, severe chronic kidney diseases,” said Alan Glicklich, M.D., chief medical officer of Chinook. “Atrasentan has been studied in over 5,300 diabetic kidney disease patients in the phase 2 RADAR an

United kingdomBritish columbiaAlan glicklichNoopur liffickJonathan barrattUniversity of leicesterChinook therapeutics incInvestor relations corporate communicationsGlomerular diseases alsoBegin enrollmentFirst halfLeicester general hospitalIga nephropathyChinook therapeuticsForward looking statementsInvestor relations